Aug 09th 2012 - Edison Investment Research today published a report on paion entitled "Sealing The Deal In China". In summary, the report says:
Formalisation of Paion’s out-licensing agreement with Yichang for the Chinese rights to short-acting anaesthetic remimazolam brings a modest financial benefit and provides some flexibility while the company identifies suitable new assets to add to its anaesthetics and critical care portfolio. Acquisition of German distribution rights to the first of these additional assets, ultra-short acting anaesthetic remifentanil, were recently announced. The increase in the proportion of day-case and minimally invasive surgeries is driving the use of short-acting general anaesthetics such as remimazolam. We have increased our valuation to €54m from €44m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
